Dublin-based medical start-up Inflazome has successfully completed a Series B financing round of €40m.
The company develops small molecule drugs that block harmful inflammation.
The latest financing round was led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also taking part.
Headquartered in Dublin, Inflazome was founded in 2016 by Professor Matt Cooper from the University of Queensland in Australia and Professor Luke O'Neill from Trinity College Dublin.
The company said the new funding will advance clinical trials of its orally-available NLRP3 inflammasome inhibitor compounds for several inflammatory diseases.
NLRP3 is associated with harmful inflammation in a broad range of serious medical conditions including Alzheimer's, Parkinson's, inflammatory bowel disease, gout, osteoarthritis, liver, kidney and cardiovascular diseases.
Dr Matt Cooper noted that Forbion and Longitude have excellent track records of working closely with biotechs to drive R&D programmes to successful clinical outcomes.
